Baxter International shares fall 2.97% amid broad market downturn

3 articles · Updated · MarketWatch · Apr 28

Baxter International Inc. closed at $17.94 on Tuesday, with trading volume reaching 9.7 million, surpassing its 50-day average.
The stock underperformed competitors such as Medtronic, Stryker, and Becton Dickinson, and is now 45.10% below its 52-week high of $32.68.
The decline occurred during a rough session for the broader market, as the S&P 500 and Dow Jones also posted losses.

Is Baxter's drastic dividend cut a savvy turnaround strategy or a final act of desperation?

How will Baxter's new smart products succeed while its core infusion pump business faces a major shipment hold?

With its CFO departing mid-crisis, can new leadership stabilize Baxter's finances and execute its recovery plan?

Do models showing Baxter is undervalued ignore the severity of its operational headwinds and leadership turnover?

Will the rapid adoption of GLP-1 drugs eventually disrupt demand for Baxter's core medical and surgical devices?